Holen Sie sich die Stockscreener-App
1.93
3.50%
-0.07
Handel nachbörslich:
1.98
0.05
+2.59%
Schlusskurs vom Vortag:
$2.00
Offen:
$2.01
24-Stunden-Volumen:
587.82K
Relative Volume:
1.16
Marktkapitalisierung:
$133.10M
Einnahmen:
$8.38M
Nettoeinkommen (Verlust:
$-27.19M
KGV:
-1.7706
EPS:
-1.09
Netto-Cashflow:
$-13.59M
1W Leistung:
-8.96%
1M Leistung:
-19.25%
6M Leistung:
+73.87%
1J Leistung:
+33.10%
1-Tages-Spanne:
$1.885
$2.02
1-Wochen-Bereich:
$1.885
$2.175
52-Wochen-Spanne:
$0.65
$2.5907
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Vergleichen Sie IRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.93 | 137.93M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-29 | Eingeleitet | Wedbush | Outperform |
| 2025-10-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Opus Genetics highlights 2025 progress, upcoming 2026 catalysts - Yahoo Finance
How Opus Genetics Inc. stock reacts to oil pricesWeekly Profit Report & Risk Controlled Daily Trade Plans - ulpravda.ru
Merger Talk: How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivalsTrade Risk Summary & Free Accurate Trade Setup Notifications - ulpravda.ru
How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivals2025 Momentum Check & Community Verified Watchlist Alerts - ulpravda.ru
Earnings Risk: Is Opus Genetics Inc. stock attractive for growth ETFsPortfolio Performance Summary & Free Community Supported Trade Ideas - ulpravda.ru
How interest rate cuts could boost Opus Genetics Inc. stock2025 Major Catalysts & Weekly Stock Performance Updates - ulpravda.ru
Opus Genetics (IRD) Advances Clinical Trials and Regulatory Fili - GuruFocus
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - The Manila Times
Opus Genetics Details 2025 Progress and 2026 Milestones - TipRanks
Opus Genetics Highlights 2025 Progress and 2026 Catalysts - TradingView — Track All Markets
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - Defense World
Independent Chairman of Opus Genetics Picks Up 9.5% More Stock - simplywall.st
Caprolactam Chemicals Limited Stock Analysis Technical Signals for YEAR - earlytimes.in
What drives Opus Genetics Inc stock priceEx-Dividend Date Alerts & Small Investment Portfolio - earlytimes.in
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Bridgewater Associates, AQR Capital Management, Schonfeld Strategic Advisors, D.E. Shaw, Millennium Management, Elliott Management, Discovery Capital Management, Opus Genetics Inc - Insider Monkey
Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update - MSN
Portfolio Shifts: How Opus Genetics Inc stock performs in stagflationWeekly Market Outlook & Low Risk High Reward Trade Ideas - moha.gov.vn
Opus Genetics (NASDAQ:IRD) Director Cam Gallagher Purchases 83,000 Shares - MarketBeat
Shorts Report: Why Opus Genetics Inc R3X1 stock is upgraded to buy - moha.gov.vn
B Riley Securities initiates coverage of Opus Genetics (IRD) with buy recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Soaring Eagle Acquisition Corp Equity Warrant Stock Analysis and ForecastLong-Term Growth Stocks & Superior Capital Appreciation - earlytimes.in
Opus Genetics Inc R3X1 Stock Analysis and ForecastMarket Insider Reports & Discover Strategies with Fellow Traders - earlytimes.in
MACD Signals Flash Warning for Compucom Software Limited StockMACD Trading Signals & Minimal Investment Big Returns - earlytimes.in
Opus Genetics rises as eye disease study to proceed without changes - MSN
Rate Hike: Why Opus Genetics Inc stock could benefit from AI revolutionInsider Selling & Proven Capital Preservation Tips - moha.gov.vn
Will Opus Genetics Inc. stock outperform growth indexesProfit Target & Consistent Growth Equity Picks - Улправда
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will Opus Genetics Inc. stock gain from lower inflationMarket Growth Summary & Low Risk Profit Maximizing Plans - Улправда
Opus Genetics partner files supplemental NDA for presbyopia drug - MSN
Why Opus Genetics Inc. stock is a value investor pick2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Bank Watch: Is Opus Genetics Inc. stock attractive for growth ETFsMarket Volume Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics Earnings Notes - Trefis
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock - MarketBeat
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) By Investing.com - Investing.com South Africa
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
Foundation Fighting Blindness Retinal Degeneration Fund Sells 4,000,000 Shares of Opus Genetics Inc (IRD) - GuruFocus
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) - Investing.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | Associated Press | syndication news - Enidnews.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - marketscreener.com
Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27% - simplywall.st
B. Riley Securities Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
B. Riley Initiates Opus Genetics at Buy With $9 Price Target - marketscreener.com
B.Riley initiates Opus Genetics stock with Buy rating on gene therapy potential - Investing.com Canada
Opus Genetics Says Independent Panel Backs Phase 1/2 Trial in Best Disease After Safety Review - marketscreener.com
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):